"Local Consolidation Therapy in Patients with EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) Receiving Frontline Osimertinib, A Real-World Experience"

Abstract

Objective: This retrospective study aims to evaluate the impact of Local Consolidation Therapy (LCT) on progression-free survival (PFS) and overall survival (OS) in patients with stage IV EGFR-mutated non-small cell lung cancer (NSCLC) receiving frontline osimertinib treatment. Methods:We conducted a chart review of patients diagnosed with stage IV EGFR-mutated NSCLC between January 2021 and May 2023, treated with osimertinib as frontline therapy. The study included 48 patients, 15 receiving LCT through either consolidation surgery or radiation. Kaplan-Meier methodology and log-rank tests were utilized to analyze PFS and OS, comparing outcomes between patients who received LCT and those who did not. Results:The median PFS for patients receiving LCT was 22.5 months, compared to 9.3 months in the non-LCT group. Similarly, the median OS was significantly improved in the LCT group, with the median OS not reached, compared to 11.9 months in the non-LCT group. No significant differences were observed between early and late consolidation radiation therapy regarding its impact on PFS and OS. Conclusion:When combined with frontline osimertinib, LCT significantly improves PFS and OS in patients with advanced EGFR-mutated NSCLC. These findings suggest that LCT is a viable and effective strategy for enhancing the outcomes of patients undergoing treatment for this challenging condition. The safety of LCT was also confirmed, with no reported complications related to the therapy. This study contributes valuable insights into the evolving treatment landscape for advanced EGFR NSCLC, highlighting the potential of LCT to augment the efficacy of systemic therapies.